severity of disease associated with viral infection in these patients [3] [4] [5] .
To our knowledge, only 1 study, which dates from the pre-HAART era, has examined the etiology of community-acquired pneumonia in HIV-infected patients, and it found standard viral pathogens to be contributory in a minority of cases [6] . Despite exhaustive testing, however, 25% of infections remained without an etiologic diagnosis, suggesting that there may be unrecognized pathogens that cause illness in HIV-infected patients. Since the publication of that study, newly identified viral pathogens, such as human metapneumovirus (hMPV) [7] , have been shown to cause severe respiratory illness, particularly among children, elderly persons, and immunocompromised patients [8, 9] . To our knowledge, no studies have examined the role of hMPV in adult HIV infection, but hMPV, like respiratory syncytial virus (RSV), certainly has the potential to be an important cause of acute respiratory illness in this population, given its predilection for causing disease in immunocompromised hosts. Clearly, the full spectrum of respiratory viral illness in this population remains to be elucidated. We undertook a prospective surveillance study of HIV-infected outpatients who consulted with health care providers at an HIV clinic for fever and respiratory symptoms, to examine the role of viral pathogens in acute respiratory tract illness in the HAART era.
METHODS

Setting.
Patients were recruited from a large university-based HIV clinic (Montreal Chest Hospital, McGill University Health Centre; Montreal, Quebec, Canada) that serves ∼950 HIVinfected adults. Although the clinic is based in a tertiary care facility, the majority of patients who are observed receive their primary care at this clinic, where there are daily walk-in clinics for nonemergency medical problems. The protocol was approved by the research ethics board of the Montreal Chest Institute. The study was advertised to patients and clinic staff through posters in the waiting area and treatment rooms.
Subjects. Consecutive patients who presented to the clinic for febrile respiratory syndromes during the period from November 2003 through April 2006 were approached during the fall, winter, and spring seasons. Respiratory infections were defined as a documented temperature of 138.0ЊC associated with у1 of the following clinical symptoms: cough, tachypnea/ dyspnea, wheezing, stridor, rhinorrhea, sore throat, and/or myalgias.
Data collection. After the patients provided informed consent, demographic and clinical data were collected from patients during consultations on a standardized questionnaire, and vital signs were recorded. Additional investigations, such as chest and sinus radiography, a complete blood cell count, and blood cultures, were performed at the discretion of the treating physician. An acute-phase serum sample was obtained during the initial consultation. Information on the duration and outcome of the episode and a convalescent-phase serum sample were obtained 2 weeks after the initial presentation.
Respiratory pathogen testing. In accordance with a standard protocol, nasopharyngeal aspirates (NPAs) were used as respiratory specimens for influenza A and B, RSV, and hMPV testing for all participants during the period from November 2003 through April 2004. After April 2004, the study protocol was amended to permit the use of combined nasal and throat swabs. Nasal swab specimens were obtained by inserting a sterile calcium alginate-tipped culture swab into the anterior nares and gently rubbing to remove some epithelial cells. Similarly, the posterior pharynx was swabbed using a second sterile swab. The 2 swabs were then combined into a single 1.5-mL vial of viral transport medium, which was composed of Hank's Balanced Salt Solution (Biowhittaker), with 5% fetal calf serum (Wisent), which was buffered with 2% 2.5M HEPES (Fischer Scientific) and supplemented with amphotericin B (500 mg/mL; Bristol-Myers Squibb), gentamicin (1600 mg/mL; Sandoz), penicillin G (20,000 U/mL; Pharmaceutical Partners Canada), and 0.002% 1N HCl. The viral media and respiratory samples were stored at 4ЊC for a maximum of 4 days and were shipped to a central laboratory, where they were stored at Ϫ80ЊC until PCR analyses were performed.
All respiratory samples were tested for the presence of a panel of 4 respiratory viruses using an in-house, real-time, multiplex RT-PCR assay, as described elsewhere [10, 11] . This assay includes 4 sets of primers for detection of influenzaviruses A (matrix) and B (matrix), RSV (fusion), and hMPV (nucleoprotein) in a LightCycler instrument (Roche Diagnostics). The different viruses (limit of detection, 50-100 copies/mL for the assay) were differentiated on the basis of their specific melting temperatures, as calculated by the LightCycler instrument. In addition, paired acute-and convalescent-phase serum samples were tested using standard complement fixation assays for viral respiratory pathogens (influenzaviruses A and B, RSV, parainfluenza virus types 1-3, and adenoviruses) [12] . A 4-fold increase in titer was considered to be diagnostic for acute respiratory infection and as additional evidence that the detection of viral pathogens by PCR was indeed associated with pathogenic infection. Also, a sputum sample was obtained from individuals with productive cough and was sent to the local microbiology laboratory for bacterial culture and antibiotic susceptibility testing.
Analysis. Patients were categorized on the basis of the presence or absence of viral infection, which was defined by a positive RT-PCR result or a significant increase in antibody titers. Baseline characteristics were compared between patients with and without viral infection using the x 2 test or Fisher's exact test for proportions, and the Wilcoxon rank sum test was used for continuous variables. Data were analyzed using SAS software, version 8.02 (SAS Institute).
RESULTS
A total of 50 patients met study criteria and consented to participate. Reasons for nonparticipation included undocumented temperature (5 patients) and refusal to provide an NPA specimen (2 patients). The median CD4 + T cell count was 325 cells/ mL (range, 2-808 cells/mL), the median HIV load was !50 copies/mL (range, !50 to 166,991 copies/mL), and 90% of participants were receiving antiretroviral therapy. Subjects who were not receiving HAART were either undergoing a treatment interruption (3 patients) or had a CD4 + T cell count 1350 cells/ mL (2 patients).
Overall, 49 of 50 patients had a respiratory specimen sufficient for PCR testing. Although acute-phase serum samples were available for all patients, paired convalescent-phase serum samples were available for only 38 patients, all of whom also had a respiratory specimen. The 1 patient without a respiratory specimen had paired serum samples. Identification of a causative pathogen was made in 25 patients (50%) using у1 method. The most frequently diagnosed infections were viral infections; there were 21 (42%) such cases: influenza A in 10 patients, influenza B in 10 patients, and parainfluenza virus type 3 infection in 1 patient. No cases of RSV, hMPV, or adenovirus infection were detected. Diagnoses of infections with viral pathogens were made by both PCR and serologic testing for 12 patients, by PCR alone for 5 patients, and by serologic testing alone for 4 patients. The concordance between PCR and serologic test results among patients who underwent both available diagnostic tests was 83.8% (proportion of patients with concordant test results, ). Similar agreement between n p 31/37 PCR and serologic test results was obtained whether NPA or nasal/pharyngeal swabs were used for collection of respiratory specimens (86% and 78%, respectively;
). There was P p .62 100% agreement with regard to the subtype of influenzavirus detected by serologic testing and PCR. The breakdown of viral infections, by calendar year, is shown in figure 1 . All cases were detected during the period from October through April for all calendar years.
Four of 12 patients with sputum culture data had cultures that yielded documented bacterial pathogens: for 3 patients, Streptococcus pneumoniae (including 2 patients with bacteremia); and for 1 patient, Neisseria meningitidis (the patient had a clinical diagnosis of pneumonia but normal chest radiograph findings). Two isolates of S. pneumoniae were resistant to erythromycin, 1 of which also displayed intermediate susceptibility to penicillin (susceptibility to trimethoprim-sulfamethoxazole was not determined). No patient had a bacterial and viral coinfection. For the remaining 25 patients (50%), no pathogen was isolated. For 5 patients, sputum samples had a WBC count of 125 cells per low-power field with !10 epithelial cells, suggesting a diagnosis of lower respiratory tract infection, although cultures yielded only normal respiratory flora. Three patients provided sputum samples that were unsuitable for culture.
Demographic and clinical characteristics of the study population, according to type of pathogen isolated, are shown in table 1. Of note, individuals with viral respiratory tract infection (influenza in 20 of 21 cases) did not differ from individuals with respiratory tract infections of bacterial or undiagnosed etiology with regard to demographic characteristics or HIV status, although a greater proportion of patients with viral infections were receiving HAART. As noted in table 2, patients with influenza were more likely to present with rhinorrhea ( ) and sore throat ( ) and were less likely to P p .09 P p .003 experience shortness of breath ( ), compared with pa-P p .05 tients who had bacterial or undiagnosed infections. No patients with influenza, compared with 23% of patients who had bacterial infection or an undiagnosed infection, had pneumonia noted by chest radiography ( ). Comparison of patients P p .07 who had influenza A (10 patients) with those who had influenza B (10 patients) revealed no statistically significant differences, although cases of influenza B tended to be less severe (e.g., fewer cases with dyspnea and wheezing and lower rates of antibiotic prescription). Patients with influenza B were less likely to have been vaccinated for influenza than were those with influenza A (9 [90%] vs. 6 [60%];
). P p .31 Antibiotic prescription was common: 70% of patients overall received antibiotics, including 12 patients (57%) with viral in- fections, even though the common cold or a flulike illness were the most common clinical diagnoses. None of the patients who received a diagnosis of influenza required hospitalization, compared with 6 patients (21%) with a bacterial or undiagnosed infection ( ). P p .03
DISCUSSION
We report what is, to our knowledge, the first prospective study of HIV-infected adults who consulted health care providers for febrile respiratory tract infection in the HAART era. We found that a very high proportion of patients had influenza A and B, even though 76% had been vaccinated. Influenza was clearly underdiagnosed, and consequently, patients were not treated appropriately. None of the patients received specific anti-influenza therapy, so potential opportunities for symptom management and reduction in infectiousness were missed. Furthermore, more than one-half of persons with influenza received antibiotics, despite an absence of radiographic changes of pneumonia, suggesting that there was a relatively low threshold for use of antibiotics in our setting. When it is unwarranted, overprescription of antibiotics may lead to unwanted adverse effects and development of antimicrobial resistance [13] . Although we observed few cases of typical bacterial pneumonia, evidence of some antibiotic resistance was present in 2 of 3 patients with S. pneumoniae infection.
The difficulty with diagnosis was likely associated with the nonspecific nature of the clinical findings, which were more characteristic of a common cold than classic influenza. Thus, there is clearly a role for rapid testing of respiratory specimens to aid in the diagnosis and treatment of HIV-infected outpatients who present with respiratory infection.
Significant changes in the pattern of respiratory illness among HIV-infected patients have been reported since the introduction of HAART. Prior to 1996, opportunistic complications, such as Pneumocystis jiroveci pneumonia and cytomegalovirus pneumonitis, predominated [6, 14] . Recent studies have indicated a substantial reduction in the risk of bacterial pneumonia in association with HAART and trimethoprim-sulfamethoxazole use [15] [16] [17] . Consistent with these reports, we identified relatively few cases of typical bacterial infection. A large proportion of patients had conditions (or infections) that remained undiagnosed and that had clinical features of pneu- monia, suggesting that other pathogens, such as Mycoplasma, Chlamydophila, and Legionella species, may have been responsible. In addition, infections caused by rhinoviruses and coronaviruses were not sought in this study. It will be important to focus on these undiagnosed infections in future studies, because they appear to be associated with significant morbidity. At 76%, the influenza vaccination rate among study participants exceeded the 70% target level set by Health Canada for individuals who were considered to be at high risk for influenza, and it was 2 times the reported average vaccination rate of 38% for this group during the 2000-2001 respiratory infection season [18] . Vaccination clearly failed to prevent infection in our population, although it may have resulted in mitigating the symptoms of influenza, making it more difficult to diagnose.
On the positive side, vaccination may also have resulted in reducing disease severity, because none of our patients experienced complications, such as pneumonia, or required hospitalization. The failure of influenza vaccination to prevent infection might have been partly related to reduced vaccine efficacy in the setting of HIV infection. Immunogenicity studies have confirmed the production of protective antibodies in HIV-infected persons, even though the antibody levels in HIV-infected persons appear to be lower than those in HIV-uninfected persons [19, 20] . However, the efficacy of influenza vaccination in preventing infection and/or clinical disease has not been widely studied. A recent meta-analysis of 4 studies that compared the incidence of influenza in vaccinated versus unvaccinated HIVseropositive subjects demonstrated only a modest benefit received from vaccination [21] .
Another possible reason why the influenza vaccine failed to prevent infection may be vaccine mismatch with the circulating strain. Our study was conducted over 3 respiratory infection seasons. There was variability in both the number of patients recruited and in the proportion of infections caused by influenza, which appears to have been directly related to the level of influenza activity in the community. The 2003-2004 season was considered to be of moderate severity in Canada. In Quebec, there was a total of 2829 influenza isolates reported from the sentinel sites of the Canadian Centre for Infectious Disease Prevention and Control Surveillance program [22] . The following season, when we recruited the largest number of patients, was a very active influenza year, with 4164 cases of influenza reported from sentinel sites in Quebec [23] . In contrast, there were only 1715 cases of influenza in Quebec during the 2005-2006 season [24] , corresponding to the low number of respiratory infections and the single case of influenza we observed in that year. Taken together, it would appear that influenza activity in the community is the primary driver behind outpatient presentation to the HIV clinic for febrile respiratory illness.
Another surprising finding was the high representation of influenza B in our population. In Quebec, all 3 time periods were characterized as predominantly influenza A seasons (99%, 90%, and 81% , respectively, of laboratory-detected infections were due influenzavirus A [22] [23] [24] ), whereas almost 50% of our patients had influenza B. Influenza A is typically associated with greater morbidity and mortality than influenza B and usually affects elderly persons, whereas influenza B is more often seen in young children. Influenza B did appear to be less severe in our population. This is, to our knowledge, the first report of a predominance of influenza B associated with HIV infection, and this predominance may in part have accounted for the benign manifestations we observed. There is no obvious reason for a predisposition to influenza B, with the potential exception of social clustering. Additional studies are needed to confirm this finding.
Our study focused on outpatients with fever and did not include all patients with respiratory symptoms; therefore, we cannot provide a measure of incidence for the various respiratory infections. We also cannot exclude the possibility that we may have missed more-severe influenza or bacterial infections in persons who presented directly to the hospital. A review of the HIV clinic database indeed revealed that 32 additional patients had pneumonia diagnosed during the same seasons. Among these patients, 14 (44%) received their diagnoses in the hospital, 9 (28%) had documented bacterial pathogens, and 1 (3%) had P. jiroveci pneumonia. Although all attempts were made to recruit all eligible patients, enrollment was limited, to some extent, by the low acceptability of NPA initially and by the lack of documented temperature (most patients who were screened and not enrolled lacked a thermometer at home and were no longer febrile at the time of presentation). Given the number of patients recruited, our failure to detect any cases of infection with other viral pathogens, such as hMPV, may have resulted from a lack of power. Finally, the lack of an HIVuninfected control group limits our ability to determine how the detection rates of respiratory pathogens in our study sample differ from those of the general population.
Although respiratory viral illnesses may be mild in nature, they accounted for a large proportion of nonscheduled visits to the health care provider for respiratory tract infections by HIV-infected patients, incurring costs both to the health care system and to patients from lost productivity. Furthermore, they were associated with unnecessary antibiotic prescriptions that may have contributed to antimicrobial resistance. Vaccination alone appears to be insufficient to prevent infection; thus, specific identification and management of infection with respiratory viruses should be performed for HIV-infected outpatients who present with fever and respiratory symptoms. Given that the median time to presentation with respiratory symptoms in patients with influenza in our study was 3 days, a significant number of cases were beyond the window of treatment with neuraminidase inhibitors (e.g., oseltamavir or zanamivir), which are active against both influenzavirus A and influenzavirus B and which should ideally be administered within 48 h after the onset of symptoms [25] . Thus, there is a role for increasing education of patients and health care providers about the role of influenza in respiratory illness and HIV to improve access to timely treatment.
Finally, the susceptibility to influenza infection among vaccinated HIV-infected patients receiving HAART raises further concerns about preparedness for pandemic influenza. Our findings suggest that HIV-infected persons may both be particularly at risk and serve as an important reservoir of infection during a pandemic or even during a widespread community outbreak. Targeting HIV-infected patients for prevention or empirical treatment of influenza in the context of a pandemic requires serious consideration.
